- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00074958
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
March 13, 2015 updated by: Genzyme, a Sanofi Company
A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
This enzyme helps to break down and remove certain types of fatty substances called "glycolipids".
These glycolipids are normally present within the body in most cells.
In people with Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities.
The build up of glycolipid levels (also referred to as "globotriaosylceramide" or "GL-3") in these tissues is thought to cause the clinical symptoms that are common to Fabry disease.
Symptoms commonly appear during childhood with pain in the hands and feet.
This study explored the safety, efficacy and pharmacokinetics of Fabrazyme in pediatric patients aged between 7 and 15 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lyon, France, Cedex 03
- Hôpital Edouard Herriot
-
Marseille, France, Cedex 05
- Hôpital de la Timone Enfants
-
Paris, France, Cedex 15
- Hopital Europeen Georges Pompidou
-
-
-
-
-
Warsaw, Poland, 04-730
- Instytut Pomnik Centrum Zdrowia Dziecka
-
-
-
-
-
London, United Kingdom, WC1N 3JH
- Great Ormond Street Hospital for Sick Children
-
-
Manchester
-
Pendlebury, Manchester, United Kingdom, M27 4HA
- Royal Manchester Children's Hospital
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 13 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patient or legal guardian must provide written informed consent
- Patients must have a clinical diagnosis of Fabry disease and active Fabry disease (clinical signs and symptoms)
- Patients must be at least 7 years of age but no older than 15 years of age at time of enrollment
- Patients must be Tanner Stage ≤ III
- Female patients must have a negative pregnancy test prior to each infusion and use a medically accepted form of contraception throughout the study
Exclusion Criteria:
- Patient has a clinically significant organic disease (with the exception of symptoms relating to Fabry disease) that in the opinion of the investigator would preclude participation in the trial
- Patient has participated in a study employing investigational drug within 30 days of the start of this study
- Patient has received prior treatment with enzyme replacement therapy
- Patient is unable to comply with the clinical protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fabrazyme
1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
|
1 mg/kg every 2 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Globotriaosylceramide (GL-3) Clearance in Capillary Endothelium in the Skin
Time Frame: Baseline, Week 24 and Week 48
|
Skin biopsies were taken at Baseline, Week 24 and Week 48 and analyzed for cellular GL-3 accumulation (inclusions) by light microscopy.
Each biopsy was evaluated by pathologists for the total number of vessels with GL-3 accumulation on an inclusion severity score of 0 (none/trace), 1 (mild), 2 (moderate), and 3 (severe).
|
Baseline, Week 24 and Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma GL-3
Time Frame: Baseline, Week 24 and Week 48
|
Plasma GL-3 values at Baseline, Week 24, and Week 48.
Normal plasma GL-3 level is ≤ 7.03 µg/mL.
|
Baseline, Week 24 and Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2002
Primary Completion (Actual)
May 1, 2005
Study Completion (Actual)
July 1, 2005
Study Registration Dates
First Submitted
December 24, 2003
First Submitted That Met QC Criteria
December 24, 2003
First Posted (Estimate)
December 25, 2003
Study Record Updates
Last Update Posted (Estimate)
April 2, 2015
Last Update Submitted That Met QC Criteria
March 13, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Fabry Disease
Other Study ID Numbers
- AGAL-016-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
University Hospital, RouenUnknownAnderson-Fabry DiseaseFrance
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael
Clinical Trials on Fabrazyme (agalsidase beta)
-
Genzyme, a Sanofi CompanyCompletedFabry DiseaseUnited States, United Kingdom, Canada, Hungary, Poland, Czech Republic
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedFabry DiseaseUnited States, France, Netherlands, Puerto Rico, United Kingdom
-
Genzyme, a Sanofi CompanyWithdrawn
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedFabry DiseaseCzech Republic, Estonia, Poland, Slovakia
-
Genzyme, a Sanofi CompanyTerminatedFabry Disease | Alpha Galactosidase A DeficiencyUnited States, Austria, United Kingdom
-
Genzyme, a Sanofi CompanyCRL/MedinetTerminatedFabry Disease | Chronic Kidney Disease, Stage IV (Severe)United States
-
Genzyme, a Sanofi CompanyCompletedFabry DiseaseUnited States, United Kingdom, Canada, Czech Republic, Hungary, Poland